Newest diabetes related technologies for pediatric type 1 diabetes and its impact on routine care : a narrative synthesis of the literature

• Autor(a) principal: Santos, Tiago Jeronimo dos
• Data de Publicação: 2021
• Outros Autores: Rodrigues, Ticiana da Costa, Puñales, Márcia Khaled, Arrais, Ricardo Fernando, Kopacek, Cristiane
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UFRGS
• Texto Completo: http://hdl.handle.net/10183/234521
• topic: Diabetes mellitus tipo 1; Sistemas de infusão de insulina; Órgãos artificiais; Revisão; Telemedicina; Type 1 diabetes; Insulin pump; Continuous glucose monitors; Closed-loop; Artifcial pancreas; Telemedicine

Purpose of Review This review aims to address the actual state of the most advanced diabetes devices, as follows: continuous subcutaneous insulin infusions (CSII), continuous glucose monitoring systems (CGM), hybrid-closed loop (HCL) systems, and “Do-it-yourself” Artifcial Pancreas Systems (DIYAPS) in children, adolescents, and young adults. This review has also the objective to assess the use of telemedicine for diabetes care across three diferent areas: education, social media, and daily care. Recent Findings Recent advances in diabetes technology after integration of CSII with CGM have increased the popularity of this treatment modality in pediatric age and shifted the standard diabetes management in many countries. We found an impressive transition from the use of CSII and/or CGM only to integrative devices with automated delivery systems. Although much has changed over the past 5 years, including a pandemic period that precipitated a broader use of telemedicine in diabetes care, some advances in technology may still be an additional burden of care for providers, patients, and caregivers. The extent of a higher rate of “auto-mode” use in diabetes devices while using the HCL/DIYAPS is essential to reduce the burden of diabetes treatment. Summary More studies including higher-risk populations are needed, and eforts should be taken to ensure proper access to cost-efective advanced technology on diabetes care.